Organoids And Spheroids Market Growth & Trends:
The global organoids and spheroids market size is expected to reach USD 3.26 billion by 2030, registering a CAGR of 23.11% during the forecast period, according to a new report by Grand View Research, Inc., A rise in the adoption of organoid cultures in drug discovery, and rising demand for cell therapy and tissue engineering across the globe is expected to drive the market.
3D spheroids are considered as an important aspect of tissue engineering and regenerative medicine research as they can be used as building blocks for the generation of complex tissues and organs. In addition, the potential of 3D cell cultures to be used as models for drug screening and analysis of human disorders are expected to provide ample growth opportunities to the market in the near future.
A rise in the adoption of organoid cultures for the assessment of the mechanism of human-specific disorders is expected to enhance the market growth. For instance, human organoids have helped in the analysis of a wide range of tissues including the small intestine, prostate, brain, and liver. The promise of the generation of 3D cell cultures that resemble human organs has brought an enormous potential for the use of organoids as cell therapies, and as prospective substitutes for whole-organ transplantation.
Organoids And Spheroids Market Report Highlights:
- The spheroids segment is anticipated to dominate the market throughout the analysis period
- Higher adoption of 3D spheroids in the fields of drug discovery, disease modeling, and safety testing is a key factor driving the segment
- The developmental biology application segment accounted for the largest revenue share in 2023 as the development of organoids from Induced Pluripotent Stem Cells (iPSCs) have paved way for dynamic observation of cell development and propelled the adoption of mechanistic studies for human development
- Biotechnology and pharmaceutical industries dominated the end-use segment in the market in 2023. This is because of the high utilization rate of organoids and spheroids in pre-clinical drug discovery by pharma entities
- In addition, these players are actively involved in the development of advanced products that enhance the efficiency of organoid and spheroid generation.
- In North America, the market generated the highest revenue in 2023 due to higher adoption of technologically advanced cell culture platforms, and the presence of a large number of universities and academic institutions actively involved in cell and organ-based studies
- In addition, a higher adoption rate of organoid and spheroid culture products and efficient healthcare infrastructure in North America is attributive to the largest revenue generation from the region
- In Asia Pacific, the market is anticipated to witness lucrative growth over the forecast period.
- Presence of key players and government organizations such as STEMCELL Technologies, Australasian Society for Stem Cell Research (ASSCR), The Japanese Society for Regenerative Medicine, The Korean Society for Stem Cell Research (KSSCR), and others are expected to enhance the penetration of organoid and spheroid culture in Asia
- The key players are constantly involved in research and development of new products so that they can enhance their market position